Phase 2 Monoclonal Gammopathy Clinical Trials
7 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–7 of 7 trials
Recruiting
Phase 2
Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance
IgA Monoclonal Gammopathy of Undetermined Significance
Fred Hutchinson Cancer Center50 enrolled1 locationNCT07209371
Recruiting
Phase 2
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Multiple MyelomaMonoclonal Gammopathy of Renal Significance
Memorial Sloan Kettering Cancer Center20 enrolled11 locationsNCT06083922
Recruiting
Phase 2
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Smoldering Multiple Myeloma (SMM)Monoclonal Gammopathy of Undetermined Significance (MGUS)
Regeneron Pharmaceuticals116 enrolled20 locationsNCT06140524
Recruiting
Phase 2
Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance
Monoclonal Gammopathy
Columbia University27 enrolled2 locationsNCT04614558
Recruiting
Phase 2
Zanubrutinib Treatment in Patients With IgM Monoclonal Gammopathy and Antri-MAG Related Polyneuropathy
Monoclonal Gammopathy of Uncertain Significance
UMC Utrecht35 enrolled1 locationNCT05939037
Recruiting
Phase 2
Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD
Monoclonal Gammopathy of Renal Significance
Peking University People's Hospital20 enrolled3 locationsNCT06418477
Recruiting
Phase 2
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
Prostate CancerMultiple MyelomaMonoclonal Gammopathy of Undetermined Significance+1 more
University of Rochester40 enrolled1 locationNCT04731844